I am proud of the progress we made over the last twelve months in achieving key corporate goals, which included gaining European regulatory approval for Vitaros®, licensing un-partnered Vitaros® territories throughout Europe, obtaining regulatory feedback from the FDA and EU authorities on Femprox®, extending our cash runway and divesting non-strategic assets.
Looking forward, our top priorities are to support our commercialization partners’ launch of Vitaros®, further advance Apricus’ second generation Vitaros® room temperature device, work with Actavis to advance the development of Vitaros® in the US, seek to out-license Femprox®, our product candidate for female sexual interest/arousal disorder (“FSIAD”), in Europe, to make definitive progress in building a robust pipeline of products in men’s and women’s health to include exploring opportunities to capitalize on our novel permeation enhancer DDAIP, and continue to invest in human capital as we seek to become a stronger and more dynamic company.
We are off to a fast start this year as we have made significant progress towards bringing Vitaros® closer to the market in 2014, our Femprox® partnering efforts have been launched, we have strengthened our Board and senior management team, and we are on our way towards building a robust pipeline of innovative products to treat an unmet need in men’s and women’s health. I firmly believe that our best days are ahead of us as we execute on the strategic plans we have put in place for 2014 and beyond. I am excited about the potential for value creation this year, and I look forward to seeing many of you on May 15th at our annual meeting of stockholders in San Diego.
Richard W. Pascoe Chief Executive Officer
Forward-Looking Statement Safe Harbor
With the exception of the historical information, the matters described herein contain forward-looking statements that involve risks and uncertainties may cause actual results to differ materially from the anticipated future results discussed above. These include risks relating to our ability to secure additional partnerships for Vitaros, the timing and success of launch of Vitaros (where approved), our ability to gain additional regulatory approvals for Vitaros and the timing and ability to commence clinical development of Femprox. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in our most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.
Our product, Vitaros®, is a topical cream for the treatment of erectile dysfunction. Vitaros® is locally applied and contains alprostadil plus our novel excipient.
Femprox® is in development for the treatment of Female Sexual Dysfunction or FSD. Like Vitaros®, Femprox® is a cream designed for local application and composed of alprostadil and our novel excipient.
We partner with world-class pharmaceutical
companies who share our passion for improving
men’s and women’s sexual health.